Sintilimab (Zybrivo)
Treatment of non-squamous non-small cell lung cancer in adults.
In 290 Chinese patients with advanced squamous NSCLC after platinum chemotherapy, sintilimab vs docetaxel improved median OS (11.79 vs 8.25 months; HR 0.74; 280 analysed) and PFS, with fewer grade ≥3 treatment-related adverse events (18.1% vs 36.2%). RCT · phase 3 · n = 290 · Cancer Commun (Lond) · 2022
Phase 2 trial, 71 untreated advanced NSCLC patients: PD-L1-guided sintilimab (alone if PD-L1 ≥50%, plus chemotherapy if <50%) met its primary endpoint (confirmed ORR 51.4%), similar to pembrolizumab; rash was commoner with sintilimab alone. RCT · phase 2 · n = 71 · Sci Bull (Beijing) · 2023